LUGPA Policy Update: HRSA Announces Revised 340B Rebate Model Pilot Program

August 2026

Overview

The Health Resources and Services Administration (HRSA) Office of Pharmacy Affairs announced a revised 340B Rebate Model Pilot Program that would allow participating pharmaceutical manufacturers to fulfill their 340B pricing obligations through a rebate-based approach rather than the traditional upfront discount model for certain covered outpatient drugs.

The Pilot follows HRSA’s review of stakeholder feedback and establishes a more formal framework for manufacturers seeking to use rebates within the 340B Program. HRSA states that the approach builds on existing rebate models already operating within portions of the program and is intended to align with broader federal drug pricing initiatives, including the Medicare Drug Price Negotiation Program established under the Inflation Reduction Act.

Key Takeaways

What Is Changing?

• The Pilot creates a pathway for participating manufacturers to provide 340B discounts through rebates rather than upfront price reductions.
• Manufacturers may apply the rebate model to selected covered outpatient drugs.
• Participating manufacturers must submit implementation plans to HRSA and comply with program requirements.

What Remains the Same?

• The statutory 340B ceiling price calculation remains unchanged.
• Covered entity eligibility requirements remain unchanged.
• Manufacturers must continue ensuring eligible entities receive the full 340B benefit.
• Existing protections against duplicate discounts and diversion remain in place.

Why It Matters

The revised Pilot represents another step in the federal government’s ongoing review of the 340B Program and prescription drug pricing policies.

HRSA indicates that the rebate model is intended to:

• Provide a consistent framework for manufacturer participation.
• Improve program administration and oversight.
• Support coordination with Medicare drug pricing reforms.
• Maintain the core requirements and protections of the 340B Program.

Potential Impact on Independent Urology Practices

Although the pilot is focused primarily on pharmaceutical manufacturers and traditional 340B covered entities, LUGPA will continue monitoring potential downstream effects on independent urology practices.

Areas of interest include:

• Physician-administered medications: Changes in manufacturer contracting, distribution, and pricing strategies could affect specialty drugs used in urologic oncology and other areas of urologic care.
• Drug acquisition costs: Any changes to pharmaceutical pricing structures may influence purchasing dynamics for independent practices.
• Competitive implications: The evolution of 340B policies may affect the broader competitive landscape between hospital-owned systems and independent physician practices.
• Future drug pricing reforms: The interaction between 340B policies and Medicare drug negotiation efforts could shape future pharmaceutical market conditions.

LUGPA Perspective

LUGPA supports policies that promote transparency, accountability, and fairness within federal drug pricing programs while ensuring patients maintain access to high-quality, community-based specialty care.

The Association continues to advocate for reforms that address market distortions, preserve physician-led independent practice, and create a level playing field between independent providers and hospital systems.

Next Steps

LUGPA staff will continue reviewing HRSA’s guidance, monitoring manufacturer participation, and evaluating any potential operational or market impacts affecting independent urology practices.

Additional analysis and member updates will be provided as implementation details become available.